Research Reports

Key takeaways

Revenue reached $1.0M from CR-001 supply transfer under Kelun License Agreement, representing first topline recognition since inception.

Net loss widened -893.4% YoY to -$23.3M versus -$2.3M, reflecting increased business activity in clinical development.

Net cash from operating activities -$8.9M, versus -$5.1M prior year, due to higher business activity and timing of vendor payments.

Full analysis

Crescent Biopharma reported Q1 FY2026 revenue of $1.0M, entirely from the initial supply transfer under the CR-001 License Agreement with Kelun. This marks the company's first revenue recognition since inception, stemming from the December 2025 deal granting Kelun exclusive Greater China rights while Crescent retains ex-China development responsibilities. The revenue reflects non-refundable upfront elements amortized over the performance period, validating the strategic partnership but remaining small relative to costs in this pre-revenue biotech stage. Investors should note this as an early milestone inflow, with potential for future amortization and payments as Kelun progresses.

CBIO · Crescent Biopharma, Inc.

Summary

Key takeaways

Full analysis